Abstract
Eighty percent (80%) of patients with Autoimmune hepatitis (AIH) respond to a combination of prednisolone and Azathioprine (AZA). Choice of treatment is limited for those who do not respond to this standard therapy. We evaluated the role of Mycophenolate mofetil (MMF) as a second line therapy in AIH. A retrospective observational study was carried out on all patients who received MMF for AIH. Twenty out of 117 patients with AIH received MMF due to AZA intolerance (18 patients) or refractory disease (2 patients). Median age of the study patients was 56 (18-79) years, Male, n = 3 (15%) and Female, n = 18 (85%). After a median follow-up period of 47 (5-83) months, 14 (73.6%) patients were still on MMF with biochemical remission, including 4 out of 5 patients with cirrhosis. One patient was lost to follow-up. Three patients were intolerant of MMF due to adverse events, and two had disease refractory to MMF. Both these patients with refractory disease to MMF were initially unresponsive to AZA therapy. MMF is a safe second line agent in patients with autoimmune hepatitis including those with cirrhosis.
References
Dec 2, 1999·Journal of Hepatology·F AlvarezM Zeniya
Oct 6, 2000·Journal of Hepatology·P D RichardsonS D Ryder
Sep 15, 2004·Journal of Clinical Gastroenterology·Bashar A AqelRolland C Dickson
Jul 7, 2005·Liver International : Official Journal of the International Association for the Study of the Liver·Nazira ChaturEric M Yoshida
Sep 8, 2005·Journal of Clinical Gastroenterology·Albert J Czaja, Herschel A Carpenter
Sep 27, 2005·Transplantation Proceedings·T M ManziaG Tisone
Nov 16, 2005·Transplantation·Jochen KluppPeter Neuhaus
May 19, 2007·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Ira Inductivo-YuMaurizio Bonacini
Jun 10, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Elke M HennesUNKNOWN International Autoimmune Hepatitis Group
Jul 1, 2008·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Jonathan T HlivkoRichard K Sterling
Dec 17, 2008·Digestive Diseases and Sciences·David C WolfEdward Lebovics
Nov 13, 2009·Journal of Hepatology·Ulf HindorfSven H C Almer
Nov 16, 2010·Journal of Gastroenterology and Hepatology·Dinesh JothimaniTim J S Cross
Jan 18, 2011·Journal of Hepatology·Kalliopi ZachouGeorge N Dalekos
Jul 16, 2011·Gut·Dermot GleesonUNKNOWN British Society of Gastroenterology
Aug 13, 2011·Transplantation·Maximilian SchmedingUlf P Neumann
Citations
Jan 23, 2016·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Ting YuLin Lin
Jan 5, 2016·Digestive Diseases and Sciences·Jonah N Rubin, Helen S Te
Jun 2, 2016·Clinical and Molecular Hepatology·Seung Woon ParkHo Sang Ryu
Mar 16, 2017·Clinical and Molecular Hepatology·Angela Cropley, Martin Weltman
Feb 15, 2019·Alimentary Pharmacology & Therapeutics·Priscila SantiagoCynthia Levy
Apr 12, 2019·Alimentary Pharmacology & Therapeutics·Amanda J NicollUNKNOWN ALA Clinical Research Network, Gastroenterological Society of Australia
Feb 5, 2019·Liver International : Official Journal of the International Association for the Study of the Liver·Iliana DoychevaAliya F Gulamhusein
Jan 19, 2016·Current Gastroenterology Reports·Craig LammertSamer Gawrieh
Aug 15, 2020·Alimentary Pharmacology & Therapeutics·Neil HallidayMichael A Heneghan
Oct 4, 2017·World Journal of Gastroenterology : WJG·Benedetta Terziroli Beretta-PiccoliDiego Vergani
Dec 30, 2020·BMJ Case Reports·Arun IyerWilliam T Gelson
Nov 3, 2020·World Journal of Gastroenterology : WJG·Mohammadreza AbdollahiBehrooz Z Alizadeh
May 5, 2021·Hepatology International·Guiqiang WangShiv Kumar Sarin
Jun 25, 2021·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Diego VerganiGiorgina Mieli-Vergani